Elderly patients with type 2 diabetes mellitus (T2DM) often have multiple coexisting diseases, and the complication of cardiovascular diseases (CVD) is the most common, which is the primary cause of disability and death. Sodium-glucose co-transporter protein 2 inhibitor (SGLT2i) is a novel hypoglycemic agent, which has received widespread attention for its cardio-protective effects, and shows good prospects for the treatment of co-morbidities of T2DM and CVD in the elderly. In this article, we reviewed the progress of SGLT2i in T2DM combined with heart failure, hypertension, atherosclerosis, myocardial infarction and other common CVD.